# Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

3

4	Matteo Stravalaci <sup>1,2*</sup> , Isabel Pagani <sup>3*</sup> , Elvezia Maria Paraboschi <sup>1,2</sup> , Mattia Pedotti <sup>4</sup> , Andrea
5	Doni <sup>1</sup> , Francesco Scavello <sup>1</sup> , Sarah N. Mapelli <sup>1</sup> , Marina Sironi <sup>1</sup> , Luca Varani <sup>4</sup> , Milos
6	Matkovic <sup>4</sup> , Andrea Cavalli <sup>4,5</sup> , Daniela Cesana <sup>6</sup> , Pierangela Gallina <sup>7</sup> , Nicoletta Pedemonte <sup>7</sup> ,
7	Valeria Capurro <sup>7</sup> , Nicola Clementi <sup>8</sup> , Nicasio Mancini <sup>8</sup> , Pietro Invernizzi <sup>9,10</sup> , Rino
8	Rappuoli <sup>11,12</sup> , Stefano Duga <sup>1,2</sup> , Barbara Bottazzi <sup>1</sup> , Mariagrazia Uguccioni <sup>4,2</sup> , Rosanna
9	Asselta <sup>1,2</sup> , Elisa Vicenzi <sup>3,§</sup> , Alberto Mantovani <sup>,1,2,13,§</sup> , Cecilia Garlanda <sup>1,2,§</sup>
10	
11	
12	<sup>1</sup> IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano (Milan), Italy;
13	<sup>2</sup> Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4,
14	20090 Pieve Emanuele (Milan), Italy;
15	<sup>3</sup> Viral Pathogenesis and Biosafety Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
16	<sup>4</sup> Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona,
17	Switzerland.
18	<sup>5</sup> Swiss Institute of Bioinformatics, Lausanne, Switzerland
19	<sup>6</sup> San Raffaele Telethon Institute for Gene Therapy (SR-Tiget); IRCCS, San Raffaele
20	Scientific Institute, Milan, Italy.
21	<sup>7</sup> UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genova
22	<sup>8</sup> Laboratory of Microbiology and Virology, IRCCS Scientific Institute and Vita-Salute San
23	Raffaele University, Milan Italy.
24	<sup>9</sup> Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of
25	Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>10</sup>European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo
- 27 Hospital, Monza, Italy
- 28 <sup>11</sup>Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, Siena, Italy.
- <sup>29</sup> <sup>12</sup>Faculty of Medicine, Imperial College London, London, UK.
- <sup>13</sup>The William Harvey Research Institute, Queen Mary University of London, Charterhouse
- 31 Square, London EC1M 6BQ.
- 32 \* equally contributed
- 33 <sup>§</sup>Corresponding authors: <u>cecilia.garlanda@humanitasresearch.it</u>,
- 34 <u>alberto.mantovani@humanitasresearch.it</u>, vicenzi.elisa@hsr.it
- 35

#### 36 Summary

37 The humoral arm of innate immunity includes diverse molecules with antibody-like functions, some of which serve as disease severity biomarkers in COVID-19. The present study was 38 39 designed to conduct a systematic investigation of the interaction of humoral fluid phase pattern recognition molecules (PRM) with SARS-CoV-2. Out of 10 PRM tested, the long pentraxin 40 41 PTX3 and Mannose Binding Lectin (MBL) bound the viral Nucleoprotein and Spike, respectively. MBL bound trimeric Spike, including that of variants of concern, in a glycan-42 dependent way and inhibited SARS-CoV-2 in three in vitro models. Moreover, upon binding 43 44 to Spike, MBL activated the lectin pathway of complement activation. Genetic polymorphisms 45 at the MBL locus were associated with disease severity. These results suggest that selected 46 humoral fluid phase PRM can play an important role in resistance to, and pathogenesis of, 47 COVID-19, a finding with translational implications.

#### 49 Introduction

50 SARS-CoV-2 is a highly pathogenic coronavirus and the causative agent of the current 51 Coronavirus disease-2019 (COVID-19) pandemic (Hartenian et al., 2020; Wu et al., 2020; Zhu 52 et al., 2020). Innate immunity is credited to play a fundamental role in this condition and may 53 eradicate the infection in its early phases, before adaptive immune responses take place. In 54 severe forms of the disease, uncontrolled activation of innate and adaptive immunity results in 55 hyperinflammatory responses, which affect the lung and blood vessels, contributing to ARDS, 56 shock and multiorgan failure (Wang et al., 2020).

57 Innate immunity includes a cellular and a humoral arm (Bottazzi et al., 2010). The humoral arm consists in soluble PRMs belonging to different families, which include collectins 58 59 [e.g. mannose binding lectin (MBL)], ficolins, pentraxins [C-reactive protein (CRP), Serum 60 amyloid P component (SAP), pentraxin 3 (PTX3)], and C1q (Bottazzi et al., 2010; Garlanda et 61 al., 2018; Holmskov et al., 2003). Humoral PRMs represent functional ancestors of antibodies 62 (ante-antibodies), as they recognize microbial components and eliminate pathogens with 63 common mechanisms that include agglutination, neutralization, activation of the complement 64 cascade and opsonization facilitating phagocytosis (Bottazzi et al., 2010). Investigations of the 65 role of humoral innate immunity in viral sensing have shown that collectins bind to envelope 66 glycoproteins on enveloped viruses, including influenza virus, human immunodeficiency virus, 67 hepatitis C virus (HCV) and herpes simplex virus, as well as to the nonenveloped rotavirus 68 (Holmskov et al., 2003). Interaction may result in opsonization, agglutination, inhibition of 69 viral fusion and entry, or complement activation, generally leading to inhibition of infection 70 (Holmskov et al., 2003). Among pentraxins, the long pentraxin PTX3 has been show to interact 71 with H3N2-subtype influenza virus type A by interacting with viral envelope hemagglutinin 72 and neuraminidase glycoproteins through a sialic acid residue on its glycosidic moiety 73 (Reading et al., 2008), with cytomegalovirus (CMV) (Bozza et al., 2006), and with the

coronavirus murine hepatitis virus strain 1 (MHV-1) (Han et al., 2012), preventing viral
infection.

Several lines of evidence, including genetic associations, indicate that cellular innate immunity, and related cytokines and chemokines, play a key role in SARS-CoV-2 recognition, antiviral resistance and, at later stages, severe disease (Merad and Martin, 2020; Pairo-Castineira et al., 2021; Severe Covid et al., 2020; Zhang et al., 2020). In contrast, little information is available concerning the role of the humoral arm of innate immunity in COVID-19 resistance and pathogenesis, in spite of the clinical prognostic significance of CRP and PTX3 (Brunetta et al., 2021; Fajgenbaum and June, 2020).

The present study was designed to conduct a systematic investigation of the interaction of the humoral PRM with SARS-CoV-2. We found that PTX3 and MBL bound the SARS-CoV-2 Nucleoprotein and Spike, respectively. MBL recognized variants of concern (VoC), had antiviral activity and activated the Complement lectin pathway. Genetic polymorphisms at the MBL locus were associated with disease severity. Thus, selected fluid phase PRM (anteantibodies) play an important role in resistance to, and pathogenesis of, COVID-19, a finding with translational implications.

90

#### 91 **Results**

#### 92 Interaction of humoral pattern recognition molecules with SARS-CoV-2 proteins

To study the role of humoral PRMs in recognizing SARS-CoV-2, we first investigated the interaction between humoral innate immunity molecules and SARS-CoV-2 proteins using a solid phase binding assay. We first analysed pentraxins and, as shown in Figure 1A and 1B, we did not observe specific binding of CRP and SAP to any of the SARS-CoV-2 proteins tested (S1, S2, S protein active trimer, Nucleocapsid, Envelope protein). In contrast, PTX3 bound specifically and in a dose-dependent manner to the Nucleocapsid protein, one of the most

99 abundant proteins of SARS-CoV-2 (Zeng et al., 2020) (Figure 1C). We validated this result by 100 confirming the binding of PTX3 with SARS-CoV-2 Nucleocapsid protein produced obtained 101 from different sources. PTX3 is a multimeric glycoprotein arranged in an octameric structure. 102 Each protomer is constituted of a flexible N-terminal region and a C-terminal domain with 103 homology to the short pentraxin family (Bottazzi et al., 2010). To define which portion of the 104 molecule was involved in the interaction, we compared the binding of full length PTX3 and its 105 N-terminal or C-terminal domains to SARS-CoV-2 Nucleocapsid protein. Results indicate that 106 PTX3 interacts with SARS-CoV-2 Nucleocapsid protein mainly through its N-terminal 107 domain, although with lower affinity compared to full length PTX3 (Figure 1D).

108 We next investigated the interaction between PRMs of the classical and the lectin 109 pathway of complement (C1q and the collectin MBL, respectively) and the viral proteins. As shown in Figure 2A, C1q did not interact with any protein tested. In contrast, human MBL 110 111 bound to SARS-CoV-2 Spike protein (Wuhan strain (Wu et al., 2020), active trimer), but not 112 to the individual SARS-CoV-2 Spike subunits S1 [containing the receptor-binding domain 113 (RBD)] and S2 (containing the membrane fusion domain) (Figure 2B). We validated these data 114 by analyzing the binding of MBL to different recombinant SARS-CoV-2 Spike proteins 115 obtained from different sources or produced in house either in HEK293 cells, or CHO cells, or 116 in insect cells (Figure 2C and Extended Data Figure 1). All these preparations were bound by 117 MBL, although with some differences. Notably, when we tested a non-covalent trimer of the 118 SARS-CoV-2 Spike protein, we did not observe binding. These results indicate that a native-119 close structure of the SARS-CoV-2 Spike protein (presumably in the trimeric conformation) is 120 indispensable for MBL recognition.

121 MBL is a member of the collectin family, a class of PRMs composed of a  $Ca^{2+}$ - type 122 lectin domain (also called Carbohydrate Recognition Domain, CRD) and a collagen-like 123 domain (Holmskov et al., 2003). Thus, we analyzed the interaction of SARS-CoV-2 Spike

protein with other collectins involved in innate immunity, such as Collectin-12 (CLP-1) and the pulmonary surfactant proteins SP-A and SP-D. We also extended the analysis to recombinant Ficolin-1, -2, or -3, a family of proteins known to activate the complement lectin pathway, and structurally-related to MBL. As shown in Figure 2D and 2E, in contrast with MBL, CLP-1, SP-A, SP-D, and ficolins did not bind to SARS-CoV-2 Spike protein, indicating that recognition of Spike is unique to MBL.

We further characterized the interaction of SARS-CoV-2 Spike protein with MBL by Surface Plasmon Resonance (SPR). Different concentrations of recombinant, SARS-CoV-2 Spike protein or RBD domain were flowed onto MBL immobilized on the biosensor surface. As shown in Figure 2F and Extended Data Figure 2, trimeric SARS-CoV-2 Spike protein formed a stable calcium-dependent complex with nanomolar affinity (K<sub>D</sub>=34 nM) whereas MBL did not bind the isolated RBD, confirming the results obtained using the S1 subunit.

136 To mimic the interaction between MBL and SARS-CoV-2 Spike protein in its 137 physiological conformation in the viral envelope, we investigated the binding of viral particles 138 of SARS-CoV-2 Spike protein pseudotyped on a lentivirus vector to MBL-coated plates. The 139 interaction was determined by lysing the bound pseudovirus and measuring the lentiviral vector 140 p24 core protein by ELISA. While control lentiviral particles pseudotyped with the VSV-g 141 glyprotein (VSV-pseudovirus) did not result in any binding, those exposing the SARS-CoV-2 142 Spike protein showed a specific interaction with MBL (Figure 3A). These data strongly suggest 143 that MBL can also interact with the SARS-CoV-2 Spike protein exposed on the virus surface.

144

#### 145 MBL interacts with glycosidic sites of the SARS-CoV-2 spike protein

146 The SARS-CoV-2 Spike protein is highly glycosylated, as recently described 147 (Watanabe et al., 2020). Out of the 22 N-glycosylation sites, 8 contain oligomannose-types 148 glycans, which could be interaction sites for the MBL carbohydrate recognition domain (CRD).

149 To address this possibility, we performed a solution-based competition assay with D-mannose 150 and N-acetyl-glucosamine, two specific ligands of the lectin. As shown in Figure 3B, D-151 mannose and N-acetyl-glucosamine inhibited MBL binding to the Spike protein, thus 152 confirming the Ca<sup>2+</sup>-dependent interaction between the MBL lectin domain and the glycosidic 153 sites exposed by the Spike protein. D-Glucose, a non-specific ligand of MBL, inhibited the 154 interaction only at higher concentration (Figure 3B). Based on the alignment of MBL crystal 155 structure with mannose molecules (Fig. 3C), we identified 14 putative binding sites on the 156 Spike protein (Fig. 3D). Next, we considered sites having a high (>80%) oligomannosylation 157 occupancy (Watanabe et al., 2020). This analysis provided two possible MBL binding sites, 158 namely N603, N801 and N1074 all on the same Spike chain, or N603, N1074 and N709 with 159 N709 on a neighboring chain (Figure 3E). Interestingly, in both cases, the hypothesized MBL 160 binding sites spans across the S1 and S2 region (Figure 3F) of the Spike protein providing hints 161 to a possible inhibition mechanism. These data indicate that the glycosylation state of the 162 SARS-CoV-2 Spike protein is important for its interaction with MBL.

163

#### 164 Interaction of MBL with Spike from VoC

165 We then tested whether MBL recognized Spike proteins from VoC. First, we analyzed 166 whether the known 22 glycosylation sites of each protomer are affected by the reported 167 mutations. Figure 3G shows a schematic representation of the 22 positions of N-linked 168 glycosylation sequons and of 35 known mutations, indicating that none of these mutations 169 involve the glycosylation sites, and suggesting that MBL could interact with the variants with 170 the same affinity. In agreement with our binding assays, no MBL target sites are expected in 171 the RBD. We assessed by solid phase assay the interaction of MBL with the SARS-CoV-2 D614G Spike trimeric protein, the B.1.1.7 variant (emerged in UK), the B.1.1.28 or P.1 variant 172

(emerged in Brazil), and B.1.351 (emerged in South Africa) (Figure 3H). In agreement with
the *in silico* analysis, MBL bound the VoC Spike proteins tested with similar affinity.

175

#### 176 **Complement lectin pathway activation**

177 We asked whether the interaction of MBL with Spike could activate the complement 178 lectin pathway. We incubated SARS-CoV-2 Spike protein-coated plates with human serum, or 179 Clq- or C4- or C3-depleted serum, and we assessed the deposition of C5b-9. As shown in 180 Figure 3I (left panel), incubation with either normal human serum or C1q-depleted serum 181 resulted in complement deposition mediated by SARS-CoV-2 Spike protein. Conversely, 182 incubation with a serum depleted of C4 strongly reduced C5b-9 deposition, with levels 183 comparable to those observed with heat-inactivated serum or C3-depleted serum. 184 Reconstitution of C4-depleted serum with purified C4 restored C5b-9 deposition levels similar 185 to those observed with normal human serum. To further address the role of MBL in SARS-CoV-2 Spike protein-mediated complement activation, we assessed C5b-9 deposition by 186 187 incubating normal human serum or MBL-immunodepleted serum over captured SARS-CoV-2 188 Spike protein, either as active, or non-covalent trimer (Figure 3I, right panel). In agreement 189 with binding data, no complement deposition was observed with the non-covalent trimeric 190 Spike protein. Notably, immunodepletion of MBL from human serum resulted in a significant 191 reduction in C5b-9 deposition, which could be fully reverted by addition of rhMBL (Figure 3I, 192 right panel). These data clearly indicate that SARS-CoV-2 Spike, by interacting with MBL, 193 activates the complement lectin pathway.

194

#### 195 SARS-CoV-2 inhibition by MBL

196To validate the relevance of the interaction between MBL and SARS-CoV-2 Spike197protein, we investigate whether MBL inhibited SARS-CoV-2 entry in susceptible cells. We

198 first tested the effect of MBL and other soluble PRMs (10-fold serial dilution, from 0.01 to 10 199 µg/ml) on the entry of the viral particles of SARS-CoV-2 Spike protein pseudotyped on a 200 lentivirus vector in 293T cells overexpressing Angiotensin-Converting Enzyme 2 (ACE2). 201 Among the soluble PRMs tested, MBL was found to be the only molecule with anti-SARS-202 CoV-2 activity. Spike-mediated viral entry was inhibited by 90% at the highest concentration 203 of 10 µg/ml (34 nM) with an EC50 value of approximately 0.5 µg/ml (1.7 nM) (Figure 4A). 204 As control, entry of lentiviral particles pseudotyped with the VSV-g glycoprotein was not 205 inhibited by MBL (Figure 4A).

206 We next tested the antiviral activity of MBL on the SARS-CoV-2 infection of lung 207 epithelial models relevant to human infections. Among a number of lung-derived epithelial cell 208 lines, Calu-3 (human lung adenocarcinoma) cells have been shown to be permissive to SARS-209 CoV-2 infection (Chu et al., 2020). SARS-CoV-2 (D614G variant, MOI=0.1 and 1) was 210 preincubated in complete medium containing different concentrations of MBL (0.01-10 211 µg/mL; 0.034-34 nM) before incubation with Calu-3 cells. After 48 and 72 h, the infectivity of 212 SARS-CoV-2 present in cell culture supernatants was determined by a plaque-forming assay 213 in monkey-derived Vero cells. Vero cells are a handy cell line used worldwide as it is devoid 214 of the interferon (IFN) response (Desmyter et al., 1968) and, for this reason, highly supportive 215 of virus replication.

As shown in Extended Data Figure 3A, MBL showed a concentration-dependent inhibition of SARS-CoV-2 infection of Calu-3 cells at MOI 0.1 (upper panel) and 1 (lower panel), that was statistically significant at 1 and 10  $\mu$ g/ml (3.4 and 34 nM) 72 h after infection. When both virus and cells were pre-incubated with the same concentrations of MBL (0.01–10  $\mu$ g/mL; 0.034-34 nM), the antiviral activity increased significantly from 0.1  $\mu$ g/ml (0.34 nM) to the top concentration of 10  $\mu$ g/ml (34 nM), 72 h post-infection (PI) (Figure 4B and Extended Data Figure 3B). The calculated EC50 was 0.08  $\mu$ g/mL (0.27 nM) at 72h. Notably, MBL showed

a concentration-dependent inhibition of infection of Calu-3 cells also by SARS-CoV-2 variant
20I/501Y.V1 (B.1.1.7) at MOI 1 (Figure 4C) and MOI 0.1 (Extended Data Figure 3C), as well
as by 20H/501Y.V2 (B.1.351) at MOI 1 (Figure 4D).

226 Furthermore, a model of 3D-human bronchial epithelial cells (HBEC) was used to test whether MBL inhibited SARS-CoV-2 replication. SARS-CoV-2 production at the 227 228 epithelial apical surface increased sharply at 48 h PI (not shown), reaching  $48 \times 10^6 \pm 6 \times 10^6$ 229 (mean ± SEM) PFU/ml 72 h PI. Treatment of HBEC with MBL decreased viral production 230 to  $4x10^6 \pm 0.8x10^6$  PFU/ml 72 h PI at the highest concentration of 50 µg/ml (170 nM) (Figure 231 5A). In contrast PTX3 treatment was ineffective at inhibiting virus production (Extended 232 Data Figure 3D). We then assessed whether in these experimental conditions, MBL affected 233 inflammatory responses in HBEC upon SARS-CoV-2 infection. As shown in Extended Data 234 Figure 3E, MBL treatment inhibited the production of IL-8 and CXCL5, chemokines 235 involved in myeloid cell recruitment and activation.

We finally evaluated occurrence of MBL-Spike protein interaction in SARS-CoV-2 infected HBEC by confocal microscopy. As shown in Figure 5B and C, MBL colocalized with SARS-CoV-2 Spike protein in infected cells. In 3D rendered images of the HBEC cell cultures (Figure 5D and Movie S1), colocalization was preferentially associated to the apical side of cytokeratin 14 positive cells. Evidence of the interaction between MBL and SARS-CoV-2 Spike protein in infected HBEC at molecular scale (<100nm *XY* spatial resolution) were also obtained in STED-based super-resolution microscopy (Figure 5E).

243

#### 244 *MBL2* haplotypes are associated with severe COVID-19

MBL2 genetic variants have been shown to correlate with increased susceptibility to selected infections, including SARS (Ip et al., 2005). To explore the significance of our *in vitro* results in the frame of COVID-19 pandemic, we investigated the possible association of *MBL2* 

248 polymorphisms with severe COVID-19 with respiratory failure in an Italian cohort of 332 cases 249 and 1,668 controls (general population). We initially focused on six SNPs known to be 250 associated with MBL2 protein levels (Table 1) (Lipscombe et al., 1992; Madsen et al., 1994; 251 Madsen et al., 1995; Sumiya et al., 1991). Surprisingly, we observed a significant difference 252 only in the frequency of the rs5030737-A allele between patients and controls (7.7% and 6.0%, 253 respectively; OR=1.43, 95%CI=1.00-2.05, P=0.049; Table 1A), which however did not survive 254 the correction for multiple testing. When we compared the frequencies of haplotypes 255 determined by all six SNPs, we found the CCGGCC haplotype frequency significantly 256 decreased in patients with severe COVID-19 (26.7% in cases, 30.4% in controls). This 257 haplotype shows a protective effect (odds ratio (OR)=0.78, 95%CI=0.65-0.95, P=0.025; Table 258 1B), consistently with the lack of the rs5030737-A allele, which is only present in the 259 CCAGCC haplotype (OR=1.38, 95%CI=1.00-1.90; P=0.078; Table 1B).

260 Though borderline, these first association results encouraged us to investigate the 1-261 Mb-long genomic region encompassing the MBL2 gene systematically. To this aim, we 262 performed single-SNP as well as haplotype-based association analyses using 263 genotyped/imputed data on 3,425 polymorphisms. Single-SNP association analysis revealed three suggestive signals (rs150342746, OR=3.47, 95%CI=1.81-6.68, P=1.86\*10<sup>-4</sup>; 264 265 rs10824845, OR=1.76, 95%CI=1.30-2.39, P=2.91\*10<sup>-4</sup>; and rs11816263, OR=1.42, 95%CI=1.17-1.73, P=3.47\*10<sup>-4</sup>; Table 1C; Figure 6), whereas haplotype-based analysis 266 267 disclosed 7 haplotypes of different lengths, from 2 to 24 SNPs, strongly associated with severe 268 COVID-19 (all surviving the correction for multiple tests; Figure 6; Table 1D). Among them, 269 the one composed of polymorphisms rs10824844-rs10824845 incorporates one of the two top-270 markers evidenced by the single-SNP association analysis and is present in 12.2% of cases and 271 6.9% of controls (TA haplotype, OR=1.88, 95%CI=1.44-2.45, P=1.04\*10<sup>-5</sup>; Table 1D). Hence, 272 we performed a meta-analysis based on the rs10824845 polymorphism by including the GHS

study of COVID-19 patients: this resulted in a pooled OR=1.32, 95%CI=1.15-1.52, P=9.12\*10<sup>-</sup> 273 274 <sup>5</sup> (Table 1E). Notably, the rs10824845 polymorphism points to a regulatory region 275 characterized by the presence of an enhancer (GH10J052964), described as a distant modulator 276 of the MBL2 gene, active in HepG2 cells (hepatocytes), as well as M0 (from venous blood) and 277 M1 (from cord and venous blood) macrophages (data from the GeneHancer database, available 278 through http://www.genecards.org/).

279

#### Discussion 280

281 Among the 10 fluid phase PRM tested in this study, only PTX3 and MBL bound SARS-282 CoV-2 virus components. PTX3 recognized the viral Nucleoprotein and had no antiviral 283 activity. PTX3 was expressed at high levels by myeloid cells in blood and lungs and its plasma 284 levels have strong and independent prognostic significance for death in COVID-19 patients 285 (Brunetta et al., 2021; Schirinzi et al., 2021). It remains to be elucidated whether PTX3 plays 286 a role in Nucleocapsid-mediated complement activation and cytokine production (Gao et al., 287 2020; Karwaciak et al., 2021; McBride et al., 2014).

288 MBL recognized the SARS-CoV-2 Spike protein, including that of three VoC, and had 289 antiviral activity in vitro. MBL had previously been shown to bind SARS-CoV Spike (Zhou et 290 al., 2010). The interaction of MBL with Spike required a trimeric conformation of the viral 291 protein, did not involve direct recognition of the RBD and was glycan-dependent, as expected. 292 Site-specific glycosylation analysis of the SARS-CoV-2 Spike protein revealed the presence 293 of various oligomannose-type glycans across the protein (Watanabe et al., 2020).

294 Molecular modelling reported here suggests that the MBL trimer interact with glycans 295 attached to the residues N603, N801 and N1074 on the same chain or N603, N709 and N1074 296 with N709 on a different chain. In both cases the hypothesized MBL binding site spans across the S1 and S2 region of SARS-CoV-2 Spike, suggesting a possible neutralization mechanism. 297

The binding of MBL could prevent the detachment of the S1 region and the release of the fusion peptide at position 815, thus inhibiting virus entry into host cells. However, the mechanisms responsible for the antiviral activity of MBL remain to be fully defined. It is noteworthy that C-type lectins have been reported to act as entry receptors (or coreceptors) (Chiodo et al., 2020; Lempp et al., 2021; Lu et al., 2021) and MBL is likely to compete at this level.

304

305 Interestingly, the *in silico* analysis presented here indicate that mutations in variants 306 reported until now do not affect glycosylation sites containing oligomannose-types glycans 307 potentially recognized by MBL. In addition, binding and infection experiments show that the 308 anti-viral activity of MBL is not affected by these mutations. This indicate that the 309 glycosylation sites are generally spared by selective pressure, suggesting they are essential for 310 SARS-CoV-2 infectivity. It has been recently shown that mechanisms of in vitro escape of 311 SARS-CoV-2 from a highly neutralizing COVID-19 convalescent plasma include the insertion 312 of a new glycan sequon in the N-terminal domain of the Spike protein, which leads to complete 313 resistance to neutralization (Andreano et al., 2020). This result further emphasizes the 314 relevance of Spike glycosidic moieties targeted by MBL in SARS-CoV-2 infectivity.

315 MBL was found to interact with Spike and have antiviral activity with an EC50 of 316 approximately 0.08 µg/ml (0.27 nM) and an affinity of 34 nM. These concentrations are well 317 in the range of those found in the blood of normal individuals (up to  $10 \mu g/ml$ ) which increase 318 2-3-fold during the acute phase response. MBL plasma levels in healthy individuals are 319 extremely variable, in part depending on genetic variation in the *MBL2* gene. Defective MBL 320 production has been associated with increased risk of infections, in particular in primary or 321 secondary immunodeficient children (Koch et al., 2001). In SARS, conflicting results have 322 been reported concerning the relevance of MBL2 genetic variants in this condition (Ip et al.,

323 2005; Yuan et al., 2005; Zhang et al., 2005). In COVID-19, one MBL2 SNP has been associated 324 with development and severity of the infection (Medetalibeyoglu et al., 2021). We investigated 325 the possible role of MBL2 genetic variants in determining susceptibility to severe COVID-19 326 with respiratory failure, by exploiting the statistical power provided by haplotype analysis. 327 Surprisingly and in contrast with a previous study (Medetalibeyoglu et al., 2021), we found 328 only a borderline correlation between one haplotype of the 6 SNPs associated with MBL levels 329 and frequency of severe COVID-19 cases. However, we found a total of 7 significantly 330 associated haplotypes, distributed along the MBL2 genomic region, often mapping in 331 correspondence of regulatory elements (such as enhancers, promoter region, histone marks; 332 Figure 6). Our association data are reinforced by: i) the meta-analysis results, obtained by 333 integrating the summary statistics from a European cohort of >113,000 individuals; ii) the fact 334 that one of our second best associations (i.e., rs10824845) maps in proximity of a cluster of suggestive signals (P<5\*10<sup>-4</sup>) identified by the COVID-19 Host Genetic Initiative 335 336 (https://www.covid19hg.org/; results on release 4 include data from up to 33 different 337 worldwide studies; Figure 6); iii) the Regeneron – Genetic Center database, which contains association results also for rare variants (MAF<1%), reports a significant association (P<0.05) 338 339 for the rs35668665 polymorphism both with susceptibility to COVID-19 (OR=4.11, GHS 340 cohort) and with severity of symptoms (OR=7.91, UK BioBank cohort). Interestingly, this 341 variant maps in correspondence of the last nucleotide of MBL2 exon 1, thus possibly interfering 342 with the splicing process; and iv) the rs5030737 (p.Arg52Cys) polymorphism in MBL2 has 343 been described in the UKBiobank ICD PheWeb database (https://pheweb.org/UKB-SAIGE/) 344 as a top signal in determining both "dependence on respirator [Ventilator] or supplemental 345 oxygen" (ICD code Z99.1; P=2.7\*10<sup>-4</sup>) and "Respiratory failure, insufficiency, arrest" (ICD 346 code J96; P= $2.7*10^{-3}$ ). These observations suggest that genetic variations in *MBL2*, possibly involved in the modulation of the expression of the gene in hepatocytes, and, interestingly, in 347

macrophages, could play a role in determining susceptibility to severe COVID-19 with
 respiratory failure. Therefore genetic analysis is consistent with the view that MBL recognition
 of SARS-CoV-2 plays an important role in COVID-19 pathogenesis.

Upon interaction with Spike, MBL was found to activate the lectin pathway of 351 complement, as expected. Complement has been credited an important role in the 352 hyperinflammation underlying severe disease and is considered a relevant therapeutic target 353 354 (Carvelli et al., 2020; Risitano et al., 2020). Therefore, as for innate immunity in general 355 including the IFN pathway (King and Sprent, 2021), MBL-mediated recognition of SARS-356 CoV-2 may act as a double-edged sword. In early phases of the disease MBL, possibly produced locally by macrophages, may serve as a mechanism of antiviral resistance by 357 358 blocking viral entry, whereas in advanced disease stages it may contribute to complement 359 activation and uncontrolled inflammation.

MBL has been safely administered to patients with cystic fibrosis and chronic lung infections in which MBL deficiency contributes to pathogenesis (Garred et al., 2002; Jensenius et al., 2003). Therefore, the results presented here have translational implications both in terms of comprehensive genetic risk assessment and development of local or systemic therapeutic approaches.

365

366

#### 367 Acknowledgements

This work was supported by a philanthropic donation by Dolce & Gabbana fashion house (to A.M., C.G., E.V.), by the Italian Ministry of Health for COVID-19 (to A.M. and C.G.), the Italian Ministry of University and Research (to P.I.), by the Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic, to P.I.).We also thank the generous contribution of Banca Intesa San Paolo, and AMAF Monza ONLUS and AIRCS for the unrestricted research funding.

374

#### 375 Author contributions

A.M. and C.G. conceived the study in March 2021 and catalyzed the interaction between

377 different Institutions; C.G., E.V. and B.B. supervised the development of the effort; M.S. and

- 378 I.P. conducted the core experimental work related to binding, antiviral activity and
- 379 Complement activation. The genetic analysis was conducted by E.M.P. supervised by S.D.
- and R.A.; A.D. performed the imaging analysis; M.P., L.V., M.M and A.C. performed SPR
- analysis and modeling; S.N.M. performed the bioinformatic analysis; M.G.U., R.R., P.I.
- 382 provided essential tools and material; F.S., Ma.S., D.C., P.G., N.P., V.C. N.C., N.M.
- 383 conducted complementary experiments.
- 384

#### 385 **Declaration of interests**

- A.M., C.G. and B.B. are inventors of a patent (EP20182181) on PTX3 and obtain royalties on
- related reagents; A.M., C.G., B.B. and E.V. are inventors of a patent (102021000002738) on
- 388 MBL. The other authors declare no competing interests.
- 389

#### 391 Figures



392

393 Figure 1. Interaction between pentraxins and SARS-CoV-2 proteins. (A-C) Recombinant 394 HiS Tag SARS-CoV-2 proteins were immobilized on 96-well Nickel coated plates at different 395 concentrations. Fixed concentrations of SAP (A), CRP (B) and PTX3 (C) were incubated over 396 the captured viral proteins. Bound pentraxins were detected by ELISA with specific primary 397 antibodies. (D) Full length PTX3 or its N- or C-terminal domains were captured on 96-well plates. Biotinylated SARS-CoV-2 Nucleocapsid protein was incubated at different 398 399 concentrations. Bound nucleocapsid was detected by ELISA using HRP-conjugated 400 streptavidin. All data are presented as mean  $\pm$  SEM of two independent experiments performed 401 in duplicate (n=4).





- 412 and Ficolin-3-coated plates were incubated with various concentrations of biotinylated SARS-
- 413 CoV-2 S protein. D-E: Bound S protein was detected by ELISA with HRP-conjugated
- 414 streptavidin (mean  $\pm$  SEM of two independent experiments in duplicate, n=4). (F) SPR shows
- 415 binding of recombinant full Spike protein trimer to immobilized MBL (K<sub>D</sub>=34 nM, left). No
- 416 binding is detected in the absence of CaCl<sub>2</sub> (right).
- 417



419 Figure 3. Interaction of MBL with SARS-CoV-2 S protein through its
420 Carbohydrate Recognition Domain (CRD). (A) MBL-coated plates were incubated with
421 different concentrations of viral particles of SARS-CoV-2 Spike protein (Spike-LV) or VSV-

422 g pseudotyped on a lentivirus vector. After lysis, bound pseudovirus was quantified by 423 measuring the released p24 core protein by ELISA. Dotted line represents p24 levels measured using the highest concentration of VSV-g pseudotyped lentivirus. Data are represented as mean 424 425  $\pm$  SEM of two independent experiments (n=6-10). (B) Biotinylated SARS-CoV-2 S protein 426 was captured on Neutravidin coated plates. MBL (0.25 µg/mL) was incubated over S protein, 427 alone or in the presence of different concentrations of D-mannose or N-acetyl-glucosamine or 428 D-glucose. Binding of free MBL was detected by ELISA. Data are presented as percentage of 429 bound MBL (mean ± SEM of two independent experiments, n=4). (C) Trimeric MBL2 model shows the distance of approximately 40 Å between mannose-binding sites. MBL2 subunits are 430 431 represented in transparent surface and cartoon, colored in cyan, blue, and dark blue; mannose 432 molecules are represented in white spheres; (D) 14 mannose-binding sites, represented as red 433 triangles, imposed onto Spike protein. Spike is represented in transparent surface and cartoon, 434 where S1 region (1-685) is colored in green, beginning of S2 region (686-815) is colored in 435 black, and S2' region is colored in white. (E) Putative binding site of MBL2. Pose with the 436 highest site-specific probability to be glycosylated with oligomannose; (F) Spike-MBL2 437 complex. Glycosylation sites are colored according to the oligomannose glycosylation 438 probability. Gold < 60%. Purple > 80% up until S2' region. Blue > 80% in the S2' region. (G) 439 Schematic representation of glycosylation sites and nucleotide substitutions in the variant 440 strains identified to date. The 8 glycosylation sites containing oligomannose-types glycans, 441 which are potential targets of MBL, are evidenced. SNPs common to all variants are in bold. 442 NTD: N terminal domain; RBD: receptor binding domain; FP: fusion peptide; HR1 and 2: 443 heptad repeat 1 and 2; cleavage sites are reported. (H) Binding of MBL to SARS-CoV-2 S 444 protein variants: recombinant SARS-CoV-2 S protein (D614G), B.1.1.7, P.1, and B.1.351 445 variants were captured onto a Nickel coated plate at different concentrations. MBL (1 µg/mL 446 -3.4 nM) was incubated over the captured viral proteins. Data are represented as mean  $\pm$  SEM,

- 447 n=3 replicates. One representative experiment out of two performed is shown for B.1.1.7. For
- 448 the other variants, one experiment was performed. (I) MAC (C5b-9) deposition on SARS-CoV-
- 449 2 Spike protein-coated plates. The assay was performed in the presence of 10% normal human
- 450 serum (NHS), C1qDHS, C4DHS, C4DHS reconstituted with C4, C3DHS, MBL-ID serum,
- 451 MBL-ID serum reconstituted with rhMBL. Mean ± SEM of two independent experiments,
- 452 performed in triplicate (n=6).
- 453





455 Figure 4. Inhibition of SARS-CoV-2 infection by MBL. (A) Entry of lentiviral 456 particles pseudotyped with SARS-CoV-2 Spike protein in 293T cells overexpressing ACE2 in 457 the presence of ten-fold serial dilutions of humoral innate immunity PRMs (from 0.01 to 10 µg/ml). As control, entry of lentiviral particles pseudotyped with the VSV-g glycoprotein was 458 459 tested in parallel in the presence of MBL. Percentage of control was calculated as ratio of GFP-460 positive cells in the presence of humoral PRMs and the GFF-positive cells in the absence of 461 humoral PRMs. Data are means  $\pm$  SEM of three independent experiments in triplicates with 462 the curves representing a three-parameter dose response model. (B-D) Inhibition of the infectivity of the D614G (isolate EPI ISL 413489) (B), B.1.1.7 (C) and B.1.351 (D) SARS-463 464 CoV-2 variants by MBL in Calu-3 cells. SARS-CoV-2 (MOI=1) and Calu-3 cells were 465 preincubated in complete medium containing different concentrations of MBL (0.01-10 µg/mL- 0.034-34 nM) before infection. After 48 and 72 h, the infectivity of SARS-CoV-2 466

- 467 present in cell culture supernatants was determined by a plaque-forming assay in Vero cells.
- 468 NIL: no MBL. Mean values of two (B) or one (C, D) experiments in duplicate cell culture are
- shown. \*\*\*\*p value <0.0001, \*\*\*p value <0.001, \*\*p value <0.01 as determined by two-way
- 470 ANOVA with Bonferroni's correction.
- 471



Figure 5. Inhibition by MBL of SARS-CoV-2 infection of primary respiratory cells. (A) 474 475 SARS-CoV-2 production at the HBEC apical surface at 72 h PI, in the presence of 10 or 50 476 µg/ml (34 or 170 nM) MBL. Mean values of three experiments in triplicate (2 donors) or single 477 (1 donor) cell cultures are shown. A: p values were determined by one-way ANOVA with Bonferroni's correction. \*\*\*\*: p value <0.0001, \*\*: p value <0.01. (B-E) Colocalization of 478 479 SARS-CoV-2 S protein and MBL in infected HBEC. (B), Confocal analysis of the localization 480 of SARS-CoV-2 S protein (green), MBL (red) in HBEC cultures infected by SARS-CoV-2 in 481 presence or not of MBL (50 µg/ml -170 nM). Left panels, merged images of fluorescence

482	signals; right panels, single signals extracted. Representative MIP images of 4-12 Z- stacks
483	acquired in tiling modality are shown. Bar, 30µm. (C) Left panel: extracted signals of SARS-
484	CoV-2 S protein and MBL of (B). Right panel: colocalization rate between SARS-CoV-2 S
485	protein and MBL (10 or 50 $\mu$ g/ml - 34 or 170 nM). Each spot corresponds to a single XYZ
486	image presented as MIP. Mean±SE. (D) 3D rendering of B right panel, showing a blended
487	reconstruction of the localization between SARS-CoV-2 S protein and MBL in HBEC cultures.
488	Left panel, contribution of merged signals. Bar, 30µm. Middle panel, extracted image of signal
489	of SARS-CoV-2 S protein and MBL. Right panel, close-up image that refers to the area dashed
490	in white. (E) STED analysis of the localization of SARS-CoV-2 S protein and MBL in HBEC.
491	Left panel, merged signals of SARS-CoV-2 S protein and MBL and nucleus; right, single
492	signals extracted. Bar, 3µm.



496 Figure 6: The *MBL2* locus: structure and main association signals with severe COVID497 19.

(A) A screenshot from the UCSC Genome browser (http://genome.ucsc.edu/; release Dec. 498 499 2013, GRCh38/hg38) specifically highlighting the 1-Mb region surrounding the MBL2 gene is 500 shown. The panel reports, in order, the following tracks: i) the ruler with the scale at the 501 genomic level; ii) chromosome 10 nucleotide numbering; iii) the UCSC RefSeq track; iv) 502 COVID-19 risk variants from our study (lollipops show only signals at P<3\*10<sup>-3</sup>); v) COVID-503 19 risk haplotypes, marked by the tagging SNP, from our study (lollipops show all haplotypes 504 reported in Table 1B and 1D); vi) COVID-19 risk variants from the COVID-19 HGI GWAS 505 Analysis C2 (17,965 cases, 33 studies, Release 4: October 2020); vii) ENCODE data

- 506 (https://www.encodeproject.org/) for H3K27Ac, H3K4Me1, H3K4Me3 histone modifications
- 507 marks, all derived from 7 cell lines; viii) the GeneHancer regulatory elements track.
- 508 (B) The Manhattan plot of the single-SNP association analysis is reported. The horizontal line
- 509 represents the suggestive  $P=5*10^{-5}$  significance level. SNPs showing lowest P value signals
- are indicated by an arrow. Bonferroni threshold for significance corresponds to  $P < 1.5*10^{-5}$ .
- 511
- 512

SNP*	rsID	Variation	A1	MAF cases	MAF controls	OR	95%CI	P*	Direction (A1) **
chr10:52771466:C:T	rs1800451	p.Gly57Glu	Т	0.017	0.021	0.814	0.39- 1.72	0.588	Lowers MBL2 levels
chr10:52771475:C:T	rs1800450	p.Gly54Asp	Т	0.017	0.15	1.070	0.83- 1.39	0.609	Lowers MBL2 levels
chr10:52771482:G:A	rs5030737	p.Arg52Cys	А	0.077	0.06	1.434	1.00- 2.05	0.049	Lowers MBL2 levels
chr10:52771701:G:A	rs7095891	Promoter region	А	0.221	0.243	0.827	0.66- 1.04	0.104	-
chr10:52771925:G:C	rs7096206	Promoter eQTL in liver (P=1.7*10 <sup>-17</sup> )	G	0.215	0.205	1.201	0.96- 1.51	0.113	Lowers <i>MBL2</i> levels
chr10:52772254:G:C	rs11003125	Promoter eQTL in liver (P=9.1*10 <sup>-6</sup> )	С	0.342	0.364	0.886	0.73- 1.09	0.236	Increases MBL2 levels

## 513 Table 1. Association analysis results514 A. Candidate SNP association analysis

515 \* Bonferroni threshold for significance is P < 0.008.

516 \*\* Direction derived from either the literature or the GTEx database (The Genotype-Tissue

517 Expression database; https://www.gtexportal.org/home/).

518

#### 519 **B. Haplotype analysis for candidate SNPs**

### 520 (rs1800451|rs1800450|rs5030737|rs7095891|rs7096206|rs11003125)

Haplotype	Frequency in cases	Frequency in controls	OR	CI	P*
CCAGCC	0.075	0.060	1.380	1.000-1.903	0.078
CCGGCC	0.267	0.304	0.785	0.651-0.946	0.025
CCGGGG	0.216	0.205	1.190	0.971-1.458	0.130
TCGACG	0.017	0.0210	0.870	0.458-1.652	0.704
CCGACG	0.205	0.222	0.833	0.678-1.023	0.121
CTGGCG	0.166	0.150	1.090	0.870-1.366	0.501
CCGGCG	0.054	0.038	1.500	1.026-2.192	0.056

\* Bonferroni threshold for significance is P < 0.05.

521 522

#### 523

#### 524 C. Locus-wide association analysis (SNPs with P<0.0050 are shown)

		•					
SNP	rsID	A1	MAF cases	MAF controls	OR	95%CI	P*
chr10:53229424:C:T	rs150342746	Т	0.026	0.008	3.474	1.808-6.676	1.86*10 <sup>-4</sup>
chr10:52963964:G:A	rs10824845	А	0.124	0.072	1.762	1.297-2.393	2.91*10-4
chr10:53083059:C:A	rs11816263	А	0.386	0.315	1.422	1.173-1.725	3.47*10-4
chr10:53104393:A:G	rs74974397	G	0.071	0.041	1.813	1.235-2.661	0.0024
chr10:53082503:A:AT	rs71032688	А	0.258	0.191	1.415	1.128-1.776	0.0025
chr10:53155596:C:T	rs117108247	Т	0.069	0.042	1.750	1.195-2.561	0.0040

525 \* Bonferroni threshold for significance is  $P < 1.5*10^{-5}$ .

526

527 528

529

529

532	<b>D.</b> Locus-wide haplotype analysis
-----	---

Haplotype	Frequency in cases	Frequency in controls	OR	CI	Р	P permutation*	SNPs**
ATCGCAA	0.006	0.043	0.133	0.049-0.36	2.26*10-7	9.99*10 <sup>-4</sup>	6 SNPs, rs11344513 rs7071467
CCC	0.005	0.073	0.058	0.019-0.182	3.12*10 <sup>-16</sup>	9.99*10 <sup>-4</sup>	3 SNPs, rs17662822 rs1159798  rs1912619
TCCCC	0.000	0.021	<1.00	nc	1.17*10 <sup>-5</sup>	0.019	5 SNPs, rs2204344 rs12218074  rs80035245 rs79357128  rs10824836
TCAGACC	0.032	0.007	4.92	2.69-9	2.59*10 <sup>-6</sup>	4.99*10 <sup>-3</sup>	5 SNPs, rs16935439 rs147096903  rs10824839 rs11003267  rs11003268
ТА	0.122	0.069	1.876	1.435-2.453	1.04*10 <sup>-5</sup>	0.018	2 SNPs, rs10824844 rs10824845
ATCCCCGC ATTGA	0.000	0.040	<1.00	nc	3.41*10-7	9.99*10 <sup>-4</sup>	9 SNPs, rs57504125  chr10:5308418:G:A
AGATCCCC GCGCGTGC AACGGCT GCGGA	0.237	0.170	1.509	1.235-1.844	3.28*10-6	4.99*10-3	24 SNPs, rs71032688 rs7092597

<sup>533</sup> \* P Value as calculated after performing 1,000 permutations to correct for multiple testing.

534 \*\* The number of SNPs composing the haplotype is indicated. All the SNPs forming the 535 haplotype are shown for short haplotypes (including max 5 SNPs). For more complex 536 haplotypes (including > 5 SNPs) only the first and the last SNPs are indicated.

537

#### 538 E. Meta-analysis for the rs10824845 polymorphism

Cohort	Cases (A1/A2 alleles)	Controls (A1/A2 alleles)	OR	95%CI	Р
Italian cohort	82/582	241/3,095	1.81	1.392-2.353	9.57*10 <sup>-6</sup>
GHS cohort	180/1,558	18,979/205,845	1.20	1.024-1.396	0.023
Summary			1.32	1.149-1.520	9.12*10 <sup>-5</sup>

539

540 In all sub-tables the SNP column is in the format chromosome:position:reference 541 allele:alternative allele. The position refers to hg38 version of the genome.

A1=minor allele; A2=major allele; CI=confidence interval; MAF=minor allele frequency;
 nc=not calculated; OR=odds ratio; rsID=reference sequence identification number;
 SNP=single nucleotide polymorphism.

545

546

#### 548 Methods

#### 549 Recombinant proteins and Antibodies

550 Commercial and non-commercial recombinant SARS-CoV-2 proteins used in this study 551 are listed in Supplementary Table 1. Recombinant human PTX3 and its domains from CHO 552 cells were produced in house, as previously described (Bottazzi et al., 1997). Recombinant 553 human Surfactant Protein-A (SP-A) was from Origene. Recombinant human MBL, Collectin-554 12 (CLP-1), Ficolin-1, Ficolin-2, Ficolin-3 and Surfactant Protein-D (SP-D) were from 555 Biotechne. Purified human C1q was from Complement Technology, purified CRP was from 556 Millipore and purified SAP was purchased from Abcam. Rabbit anti-PTX3 antibody was 557 produced in house (Bottazzi et al., 1997), rabbit anti-MBL Ab was purchased from Abcam. 558 Anti-C1q polyclonal antibody was purchased from Dako. Anti-CRP and anti-SAP antibodies 559 were from Merck.

#### 560 Binding of Humoral Pattern Recognition Molecules to SARS-CoV-2 proteins

561 Recombinant His-Tag SARS-CoV-2 proteins were immobilized at different 562 concentrations (ranging from 6.25 to 50 pmol/mL) on 96-well Nickel coated plates (Thermo Fisher Scientific) for 1 h at room temperature. Plates were then blocked for 2 h at 37°C with 563 564 200 µL of 2% BSA diluted in 10 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl, 2 565 mM CaCl<sub>2</sub> and 0.1% Tween-20 (TBST-Ca<sup>2+</sup>). Following blocking, plates were washed three 566 times with TBST-Ca<sup>2+</sup> and incubated for 1 h at 37°C with 100  $\mu$ L PTX3 (4  $\mu$ g/mL - 12 nM in TBST-Ca<sup>2+</sup>), MBL (1-2 µg/mL - 3.4-6.7 nM in TBST-Ca<sup>2+</sup>), C1q (4 µg/mL - 10 nM in TBST-567 Ca<sup>2+</sup>), CRP (3  $\mu$ g/mL – 25 nM in TBST-Ca<sup>2+</sup>) and SAP (4  $\mu$ g/mL – 32 nM in TBST-Ca<sup>2+</sup>). 568 569 After washes, plates were incubated for 1 h at 37°C with specific primary antibodies, followed 570 by the corresponding HRP-conjugated secondary antibodies. Both primary and secondary 571 antibodies were diluted in TBST-Ca<sup>2+</sup> buffer. After development with the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB, Thermo Fisher Scientific, USA), binding was 572

detected by absorbance reading at 450 nm on a Spectrostar Nano Microplate Reader (BMG
Labtech, Germany). Values from blank wells were subtracted from those recorded at sample
wells.

576 In another set of experiments, 100 µL of 2 µg/mL rhMBL (6.7 nM), CLP-1 (6.7 nM), 577 Ficolin-1 (5 nM), Ficolin-2 (5 nM), and Ficolin-3 (3 nM), SP-A (3 nM) or SP-D (3.4 nM) in 578 PBS were immobilized on 96-well Nunc Maxisorp Immunoplates (Costar, USA) overnight at 4°C. Plates were blocked with 200 µL of 2% BSA-TBST-Ca<sup>2+</sup> for 2 h at 37°C. After washes, 579 100 µL of biotinylated SARS-CoV-2 S protein was added at different concentrations to the 580 581 plates for 1 h at 37°C. Following washes, HRP-conjugated streptavidin (1:10000, Biospa) was 582 incubated for 1 h at 37°C. Specific binding was detected by TMB development, as described 583 above.

For competition-based experiments, biotinylated SARS-CoV-2 S protein was captured on 96-wells Neutravidin coated plates for 1 h at 37°C. Plates were then incubated for 1 h at 37°C with 100  $\mu$ L rhMBL (0.25  $\mu$ g/mL- 0.83 nM) alone or in the presence of various concentrations of D-mannose or N-acetyl-glucosamine, or D-glucose (Sigma Aldrich). Bound MBL was detected by incubation with rabbit anti-MBL antibody, followed by HRP-conjugated secondary antibody and TMB development, as described above.

590 For the experiments on the interaction between PTX3 domains and SARS-CoV-2 591 Nucleocapsid, PTX3 and its recombinant domains were immobilized on the wells of a 96-well 592 Nunc Maxisorp plate. Then, different concentrations of biotinylated SARS-CoV-2 593 Nucleocapsid protein were added over the captured proteins for 1 h at 37°C. Detection of 594 binding was achieved through incubation with HRP-conjugated streptavidin, as detailed above.

595 Surface plasmon resonance (SPR) studies

SPR analyses were carried out at 25 °C on a Biacore 8K instrument (GE Healthcare).
MBL was immobilized on the surface of a CM5 sensor chip through standard amine coupling.

Briefly, after activation of the surface with a mixture of 1-Ethyl-3-(3-dimethylaminopropyl) 598 599 carbodiimide hydrochloride and N-Hydroxysuccinimide, MBL was diluted at 50 nM in 10 mM 600 sodium acetate buffer, pH 4.5 and injected over the surface (flow rate 10 µl/min). Free activated 601 sites were blocked by flowing 1 M Ethanolamine, pH 8.5. Final MBL immobilization levels 602 were around 4500 Resonance Units (RU, with 1 RU = 1  $pg/mm^2$ ). A second surface was 603 prepared in parallel with the same procedure, but without any ligand, and used as reference. 604 Recombinant RBD and trimeric Spike were produced in EXPI293 cells and purified as reported 605 (De Gasparo et al., 2021). Increasing concentration of SARS-CoV-2 RBD or Spike protein 606 (2.5, 7.4, 22, 67, 200 and 600 nM) were injected using a single-cycle kinetics setting at a flow 607 rate of 30 µl/min; dissociation was followed for 10 minutes. The running buffer (also used to 608 dilute samples) was 10 mM Tris-buffered saline, pH 7.4, containing 150 mM NaCl, 2 mM 609 CaCl<sub>2</sub> and 0.005% Tween-20. In another set of experiments, the interaction was analyzed using 610 the running buffer without CaCl<sub>2</sub>. Analyte responses were corrected for unspecific binding and 611 buffer responses through the use of reference channels. Binding kinetics were determined by 612 fitting of the experimental curves with the Langmuir 1:1 model according to standard 613 procedures; data analyses were performed with Biacore<sup>™</sup> Insight Evaluation Software 614 v2.0.15.12933. In the presence of CaCl<sub>2</sub>, trimeric Spike bound to MBL with  $K_a$  (1/Ms)= 2.1e<sup>+</sup>4, 615  $K_d (1/s) = 7.3e^{-4}$  and  $K_D = 34$  nM.

#### 616 Computational modeling of the MBL2 SARS-CoV-2 Spike interaction

The model of the MBL2 trimer (UniProt(Consortium, 2020) P11226) was created starting from the crystal structure of human mannose binding protein(Sheriff et al., 1994) (PDB code 1HUP). The N-terminus of MBL2 was modeled as collagen, based on the template crystal structure of collagen triple helix model(Berisio et al., 2002) (PDB code 1K6F). The binding site of mannose molecules was determined aligning the MBL2 structure to the crystal structure

of rat mannose protein A(Ng et al., 2002) (PDB code 1KX1). Reference distances (~ 40 Å)
between mannose molecules were computed in PYMOL.

Putative binding sites of MBL2 were determined identifying all triplets of Nglycosylation sites at a distance between 35 Å and 50 Å in the closed state SARS-CoV-2 (Casalino et al., 2020). Distances were computed using the program ALMOST(Fu et al., 2014).

#### 627 **Pseudotyped virus production**

Human embryonic kidney 293T cells were transfected with a lentiviral vector 628 629 expressing the Green Fluorescent Protein (GFP) under the control of a human 630 Phosphoglycerate Kinase promoter (PGK) (Cesana et al., 2014) and a pCMV expressing vector containing the SARS-CoV-2 Spike sequence (accession number MN908947) that was codon-631 632 optimized for human expression and contained a deletion at the 3' end aimed at deleting 19 633 amino acid residues at the C-terminus. An HIV gag-pol packaging construct and a rev-634 encoding plasmid were co-transfected by calcium phosphate for the production of infective 635 viral particles. 16 h after transfection, the medium was replaced and 30 h later, supernatant was 636 collected, filtered through 0.22 um pore nitrocellulose filter and viral particles were pelleted by ultracentrifugation. As control, lentivirus particles were pseudotyped with the VSV-g 637 638 glycoprotein that allows a high efficiency infection independently of binding to ACE2.

#### 639 **Pseudotyped lentivirus binding assay**

640 96-well Nunc Maxisorp Immunoplates (Costar, USA) were coated with 100  $\mu$ L of 641 rhMBL (3 and 1  $\mu$ g/mL – 10 and 3.4 nM diluted in PBS). After overnight incubation, plates 642 were blocked with 2% BSA diluted in TBST-Ca<sup>2+</sup> for 1 h at 37°C, washed three times with 643 TBST-Ca<sup>2+</sup> and incubated for 1 h with 100  $\mu$ L of SARS-CoV-2 Spike protein-pseudotyped 644 lentivirus or VSV-pseudotyped lentivirus (ranging fom 0.1 to 1  $\mu$ g/mL diluted in TBST-Ca<sup>2+</sup>). 645 After washing, bound pseudotyped virus particles were lysed with 0.5% Triton X-100 and HIV 646 p24 core protein was detected by ELISA (Perkin Elmer; USA).

#### 647 Complement deposition assay

648 100 µL of biotinylated SARS-CoV-2 Spike protein (either active trimer or non-covalent 649 trimer, 1µg/mL in PBS) were captured on 96 well plates for 1 h at 37°C. After washing, wells were incubated for 1 h at 37°C with either 10% normal human serum (NHS, ComplemenTech 650 651 Inc, USA), 10% C1q-depleted serum (C1qDHS), 10% C4-depleted serum (C4DHS) reconstituted or not with 25 µg/mL purified C4 (Calbiochem, USA). 10% heat-inactivated 652 653 human serum (30' at 56°C, HI-NHS) and 10% C3-depleted serum (C3DHS) were used as 654 negative control. All the sera were diluted in 10 mM Tris-buffered saline containing 0.5 mM 655 MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub> and 0.05% Tween-20, also used as washing buffer. For MBL 656 immunodepletion, 10% NHS was incubated overnight with 0.6 µg/mL rabbit anti-MBL 657 antibody. Bound MBL-antibody complexes were separated by Dynabeads Protein G (Thermo 658 Fisher Scientific), and the supernatant (termed MBL-ID) was used in the assay (final 659 concentration, 10%). After washing, C5b-9 deposition was assayed by incubation for 1 h at 660 37°C with rabbit anti-sC5b-9 antibody (ComplemenTech Inc., Usa) diluted 1:2000 in washing 661 buffer as described before (Stravalaci et al., 2020), followed by specific HRP-conjugated secondary antibody incubation and TMB development. 662

#### 663 Cell Lines

664 The Vero and Vero E6 cell line was obtained from the Istituto Zooprofilattico of 665 Brescia, Italy, and ATCC, respectively. Cells were maintained in Eagle's minimum essential 666 medium (EMEM; Lonza) supplemented with 10% fetal bovine serum (FBS; Euroclone) and 667 penicillin-streptomycin (complete medium).

Human embryonic kidney 293T cells, a continuous human embryonic kidney cell line
containing the mutant gene of SV40 Large T Antigen (ATCC code CRL-3216), were cultured
as described (Follenzi et al., 2000).

The human lung epithelial Calu-3 cell line was obtained from NovusPharma. Cells were grown in EMEM supplemented with 20% FBS and penicillin-streptomycin (complete medium).

674 Human Bronchial Epithelial Cells (HBEC)

675 The isolation, culture, and differentiation of primary human bronchial epithelial cells 676 (HBECs) were performed as previously reported (Scudieri et al., 2012), with some 677 modifications. In brief, epithelial cells were obtained from mainstem human bronchi, derived 678 from individuals undergoing lung transplant. For the present study, cells were obtained from 679 three donors (BE37, BE63 and BE177). Epithelial cells were detached by overnight treatment 680 of bronchi with protease XIV and then were cultured in a serum-free medium (LHC9 mixed 681 with RPMI 1640, 1:1) containing supplements, as described (Scudieri et al., 2012). The 682 collection of bronchial epithelial cells and their study to investigate airway epithelium 683 physiopathology were specifically approved by the Ethics Committee of the Istituto Giannina 684 Gaslini following the guidelines of the Italian Ministry of Health (registration number: 685 ANTECER, 042-09/07/2018). Each patient provided informed consent to the study using a 686 form that was also approved by the Ethics Committee.

To obtain differentiated epithelia, cells were seeded at high density  $(5x10^5$ cell/snapwell) on 12-mm diameter porous membranes (Snapwell inserts, Corning, code 3801). After 24 hours, the serum-free medium was removed from both sides and, on the basolateral side only, replaced with Pneumacult ALI medium (StemCell Technologies) and differentiation of cells (for 3 weeks) was performed in air-liquid interface (ALI) condition.

#### 692 Entry assay with SARS-CoV-2 Spike- pseudotyped lentivirus particles

693 293T cells were engineered to overexpress the SARS-CoV-2 entry receptor by
694 transduction of a lentiviral vector expressing ACE2 (kindly provided by Massimo Pizzato,
695 University of Trento). Lentiviral vector stock expressing ACE2 was produced as described

above. The entry assay was then optimized in 96-well plate by seeding  $5x10^4$  ACE2 overexpressing 293T cells/well. Twenty-four h later, cells and SARS-CoV-2 Spikepseudotyped lentivirus stock (1:500) were incubated with serial dilutions of soluble innate immunity molecules for 30 min. The SARS-CoV-2 Spike-pseudotyped was added to the cells and forty-eight h later, cells were treated with accutase, in order to detach them from the wells, fixed and analyzed for GFP expression by cytofluorimetry.

#### 702 SARS-CoV-2 viral isolates

703 The SARS-CoV-2 isolate of the B.1 lineage with the Spike D614G mutation (GISAID 704 accession ID: EPI ISL 413489) was obtained from the nasopharyngeal swab of a mildly 705 symptomatic patient by inoculation of Vero E6 cells as described (Clementi et al., 2020; 706 Mycroft-West et al., 2020). The SARS-CoV-2 isolate of the South African B1.351 lineage 707 (GISAID accession ID: EPI ISL 1599180) was obtained from the nasopharyngeal swab of an 708 Italian 80-year-old male patient. The SARS-CoV-2 isolate of the B1.1.7 lineage (GISAID 709 accession ID: EPI ISL 1924880) was obtained from the nasopharyngeal swab of an Italian 710 58-year-old female patient. Secondary viral stocks were generated by infection of adherent 711 Vero E6 cells seeded in a 25 cm<sup>2</sup> tissue culture flask with 0.5 ml of the primary isolate diluted 712 in 5 ml of complete medium. Three days after infection, the supernatant was harvested and, 713 after centrifugation, passed through a 0.45 µm filter. Aliquots of the secondary SARS-CoV-2 714 isolate were maintained at -80 °C. A plaque-forming assay was performed to determine viral 715 titers.

#### 716 Infections

Calu-3 cells were seeded in 48-well plates (Corning) at the concentration of  $5x10^4$ cell/well in complete medium 24 h prior to infection. Ten-fold serial dilutions of MBL (from 0.01 to 10 µg/ml – 0.034-34 nM) were incubated for 1 h with aliquots of SARS-CoV-2 containing supernatant to obtain a multiplicity of infection (MOI) of either 0.1 or 1 before

incubation with Calu-3 cells (Virus+MBL). After 48 and 72 h post-infection (PI), cell culture
supernatants were collected and stored at – 80 °C until determination of the viral titers by a
plaque-forming assay in Vero cells.

724 Virus incubation with MBL was also combined with incubation of target cells. Briefly, 725 virus incubation with MBL was performed as described above whereas Calu-3 cells were 726 incubated with 10-fold serial dilutions of MBL (from 0.01 to  $10 \,\mu\text{g/ml} - 0.034-34 \,\text{nM}$ ). After 727 1 h, virus suspensions incubated with serial dilutions of MBL were added to MBL-treated cells 728 (Virus+ Cells+MBL). After 48 and 72 h POST, cell culture supernatants were collected and 729 stored at -80 °C until determination of the viral titers by a plaque-forming assay in Vero cells. 730 Forty-eight h before infection, the apical surface of HBEC was washed with 500 µl of 731 PBS for 1.5 hours at 37°C, and the cultures were moved into fresh air liquid interface media. 732 Immediately before infection, apical surfaces were washed twice to remove accumulated 733 mucus with 500 µl of PBS with each wash lasting 30 min at 37°C. Two concentrations of either 734 PTX3 or MBL were added to the apical surface for 1 h prior to the addition of 100 µl of viral 735 inoculum (SARS-CoV-2) at a MOI of 1. HBEC were incubated for 2 h at 37°C. Viral inoculum 736 was then removed and the apical surface of the cultures was washed three times with 500 µl of PBS. Cultures were incubated at 37°C for 72 h PI. Infectious virus produced by the HBEC was 737 collected by washing the apical surface of the culture with 100 µl of PBS every 24 h up to 72 738 739 h PI. Apical washes were stored at -80°C until analysis and titered by plaque assay in Vero 740 cells. At 72 h PI, cells were fixed in 4% paraformaldehyde for immunofluorescence analysis. 741 All infection experiments were performed in a biosafety level 3 (BSL-3) laboratory at the 742 Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University.

743 Chemokine quantification

Half of the ALI medium (1 ml) was collected from each well of the lower chamber
every 24 h PI and replaced with fresh ALI medium. The harvested medium was stored at -70

<sup>746</sup> °C until analysis. Prior to chemokine quantification, 250 μl of medium was treated with 27 μl

747 of Triton X-100 and heated for 30 min at 56 °C to inactivate SARS-CoV-2 infectivity.

748 Chemokines (IL-8 and CXCL5) were quantified by ELISA (Quantikine ELISA kits,

code DY208, DY254, R&D Systems).

#### 750 Plaque-forming assay

751 In order to measure the virus titer of the viral stocks, a plaque-forming assay was optimized in Vero cells. Briefly, confluent Vero cells  $(1.5 \times 10^6 \text{ cell/well})$  seeded in 6-well 752 753 plates (Corning) were incubated in duplicate with 1 ml of EMEM supplemented with 1% FBS 754 containing 10-fold serial dilutions of SARS-CoV-2 stock. After 1 h of incubation, the viral 755 inoculum was removed and methylcellulose (Sigma; 1 ml in EMEM supplemented with 5% 756 FBS) was overlaid on each well. After 4 days of incubation, the cells were stained with 1% crystal violet (Sigma) in 70% methanol. The plaques were counted after examination with a 757 758 stereoscopic microscope (SMZ-1500; Nikon Instruments) and the virus titer was calculated in 759 terms of plaque forming units (PFU)/ml.

In order to determine the viral titers of the supernatant collected from Calu-3 cells at 48 and 72 h PI, confluent Vero cells  $(2.5 \times 10^5 \text{ cell/well})$  were seeded in 24-well plates (Corning) 24 h prior to infection. Then, cells were incubated with 300 µl of EMEM supplemented with 1% FBS containing serially diluted (1:10) virus-containing supernatants. The plaque-forming assay was performed as described above.

#### 765 Confocal and STED super-resolution microscopy

After 4% PFA fixation, HBEC cultures were incubated for 1 h with PBS and 0.1%
Triton X-100 (Sigma-Aldrich), 5% normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05%
Tween (blocking buffer). Cells were then incubated for 2 h in blocking buffer with the
following primary antibodies: mouse anti-cytokeratin 14 (Krt14) (#LL002; 1µg/ml; cat. N° 33168, ProSci-Incorporated, US); rabbit polyclonal anti-Spike protein (944-1218aa) (2µg/ml; cat.

771 N° 28867-1-AP, Proteintech®, Germany); rat anti-MBL (#8G6; 1µg/ml; cat. N°HM1035, 772 Hycult<sup>®</sup>Biotech) and rat anti-MBL (#14D12; 1µg/ml; cat. N°HM1038, Hycult<sup>®</sup>Biotech). After 773 washing with PBS and 0.05% Tween, cells were incubated for 1 h with the following species-774 specific cross-adsorbed secondary antibodies form Invitrogen-ThermoFisher Scientific: donkey anti-rabbit IgG Alexa Fluor<sup>®</sup> 488 (1µg/ml; cat. N° A-21206); donkey anti-rat IgG 775 Alexa Fluor<sup>®</sup> 594 (1µg/ml; cat. N° A-21209); donkey anti-mouse IgG Alexa Fluor<sup>®</sup> 647 776 777 (1µg/ml; cat. N° A-31571). 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen) was used for 778 nucleus staining. Cells were mounted with Mowiol® (Sigma-Aldrich) and analyzed with a Leica SP8 STED3X confocal microscope system equipped with a Leica HC PLAPO CS2 779 63X/1.40 oil immersion lens. Confocal images (1.024 X 1.024 pixels) were acquired in XYZ 780 781 and tiling modality (0.25 µm slice thickness) and at 1 Airy Unit (AU) of lateral resolution 782 (pinhole aperture of 95.5µm) at a frequency of 600Hz in bidirectional mode. Alexa Fluor 488® 783 was excited with a 488 nm argon laser and emission collected from 505 to 550nm. Alexa Fluor 594<sup>®</sup> was excited with a 594/604nm-tuned white light laser and emission collected from 580 784 to 620nm. Alexa Fluor 5647<sup>®</sup> was excited with a 640/648nm-tuned white light laser and 785 786 emission collected from 670 to 750nm. Frame sequential acquisition was applied to avoid fluorescence overlap. A gating between 0.4 and 7ns was applied to avoid collection of 787 788 reflection and autofluorescence. 3D STED analysis was performed using the same acquisition 789 set-up. A 660 nm CW-depletion laser (30% of power) was used for excitations of Alexa Fluor 790 488<sup>®</sup> (Spike signal) and Alexa Fluor 594<sup>®</sup> (MBL signal). STED images were acquired with a 791 Leica HC PL APO 100×/1.40 oil STED White objective at 572.3 milli absorption unit (mAU). CW-STED and gated CW-STED were applied to Alexa Fluor 488<sup>®</sup> and Alexa Fluor 594<sup>®</sup>, 792 respectively. Confocal images were processed, 3D rendered and analyzed as colocalization rate 793 794 between Spike and MBL with Leica Application Suite X software (LASX; version 795 3.5.5.19976) and presented as medium intensity projection (MIP). STED images were de-

convolved with Huygens Professional software (Scientific Volume Imaging B. V.; version19.10) and presented as MIP.

798 Patient cohorts for genetic analyses

For association analyses, we investigated a total of 2,000 individuals. These included: i) 332 patients with severe COVID-19, which was defined as hospitalization with respiratory failure and a confirmed SARS-CoV-2 viral RNA PCR test from nasopharyngeal swabs. Patients were recruited from intensive care units and general wards at two hospitals in the Milan area, i.e., the Humanitas Clinical and Research Center, IRCCS, in Rozzano, Italy (140 patients); and San Gerardo Hospital, in Monza, Italy (192 patients); ii) 1,668 controls from the general Italian population with unknown COVID-19 status.

Details on DNA extraction, array genotyping and quality checks are reported elsewhere (Myocardial Infarction Genetics et al., 2009; Severe Covid et al., 2020). The dataset for cases was submitted to the European Bioinformatics Institute (<u>www.ebi.ac.uk/gwas</u>) under accession numbers GCST90000255 and GCST90000256, whereas the dataset for controls is deposited in the Genotypes and Phenotypes database (dbGaP; <u>https://www.ncbi.nlm.nih.gov/gap/</u>), under the phs000294.v1.p1 accession code.

Approvals for the project were obtained from the relevant ethics committees (Humanitas Clinical and Research Center, reference number, 316/20; the University of Milano-Bicocca School of Medicine, San Gerardo Hospital, reference number, 84/2020).

815 Imputation

Genetic coverage was increased by performing single-nucleotide polymorphism (SNP)
imputation on the genome build GRCh38 using the Michigan Imputation Server
(https://imputation.biodatacatalyst.nhlbi.nih.gov/index.html#!) and haplotypes generated by
the Trans-Omics for Precision Medicine (TOPMed) program (freeze 5) (Taliun et al., 2021),
for both cases and controls. In the imputation, we used the population panel "ALL" and applied

the server options to filter by an imputation of  $R^2>0.1$ . In the post-imputation steps, we only retained those SNPs with  $R^2\geq0.6$  and minor allele frequency (MAF)  $\geq1\%$ . Next, we accurately checked cases and controls for solving within-Italian relationships and for testing the possible existence of population stratification within and across batches: to this aim, we performed principal component analysis (PCA), using a LD-pruned subset of SNPs across chromosome 10 and the Plink v.1.9 package (Chang et al., 2015). The final set of analyzed variants comprised 3,425 SNPs, distributed in the *MBL2* region (the gene +/-500 kb).

#### 828 Statistical analysis

Prism GraphPad software v. 8.0 (<u>www.graphpad.com</u>) was used for the statistical analyses. Comparison among groups were performed using one or two-way analysis of variance (ANOVA) and the Bonferroni's correction. Non-linear fit of transformed data was determined by using the log (agonist) vs. response (three or four parameters).

For genetic studies, case-control allele-dose association tests were performed using the PLINK v.1.9 logistic-regression framework for dosage data. Age, sex, age\*age, sex\*age, and the first 10 principal components from PCA were introduced in the model as covariates. Analyses were conducted always referring to the minor allele. All P values are presented as not corrected and accompanied by odds ratio (OR) and 95% confidence interval (CI); however, in the relevant table/figure, Bonferroni-corrected thresholds for significance are indicated in the footnote/legend.

840 Haplotype analysis was performed in two ways: i) by selecting relevant SNPs and using the -hap-logistic option implemented in PLINK v.1.07 (Purcell et al., 2007); ii) by an 841 842 unsupervised of approach by means the Beagle software v3.3 843 (http://faculty.washington.edu/browning/beagle/b3.html), which uses the method described by 844 Browning & Browning (Browning and Browning, 2007) for inferring haplotype phase. In this 845 case, we used the default setting of 1,000 permutations for calculating corrected P values.

- In the meta-analysis, we took advantage of association data deposited in the Regeneron
  Genetic Center database (<u>https://rgc-covid19.regeneron.com/home</u>) for the GHS study
  (Geisinger Health System; data available for 869 cases and 112,862 controls of European
  ancestry). Pooled Ors and Cis were calculated using the Mantel-Haenszel model (Mantel and
  Haenszel, 1959)
- 851

### 852 Supplementary information

853

### 854 Supplementary Table 1. Recombinant SARS-CoV-2 proteins used in this study.

Proteins	Host	Cat	Company
SARS-CoV-2 S1 protein, His Tag	HEK293	S1N-C52H4	ACROBiosystems
SARS-CoV-2 S2 protein, His Tag	HEK293	S2N-C52H5	ACROBiosystems
SARS-CoV-2 S protein, His Tag, active trimer	HEK293	SPN-C52H8	ACROBiosystems
SARS-CoV-2 Nucleocapsid protein, His Tag	HEK293	NUN-C5227	ACROBiosystems
SARS-CoV-2 Envelope protein. GST, His Tag	E.coli	ENN-C5128	ACROBiosystems
Biotinylated SARS-CoV-2 S protein, His Tag, active			
trimer	HEK293	SPN-C82E3	ACROBiosystems
Biotinlyated SARS-CoV-2 Nucleocapsid protein, His Tag	HEK293	NUN-C82E8	ACROBiosystems
SARS-CoV-2 S protein, His Tag	HEK293	10549-CV	R&D Systems
SARS-CoV-2 Nucleocapsid protein, His Tag	HEK293	230-30164	RayBiotech
			(Andreano et al.,
SARS-CoV-2 S protein, His Tag	HEK293	In house	2020)
			(De Gasparo et al.,
SARS-CoV-2 S protein trimer, His Tag	EXPI293F cells	In house	2021)
		XLGCOV-1-	
SARS-CoV-2 S protein, His Tag	СНО	РРТН	ExcellGene
SARS-CoV-2 (2019-nCoV) Spike RBD, His Tag	HEK293	40592-V08H	Sino Biological
	Insect		
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD, His Tag	cells	40589-V08B1	Sino Biological
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD (B.1.1.7),	Insect		
His Tag	cells	40589-V08B6	Sino Biological
SARS-CoV-2 S protein (D614G), His Tag	HEK293	SPN-C52H3	ACROBiosystems
SARS-CoV-2 S protein (B.1.1.7 variant), His Tag	HEK293	SPN-C52H6	ACROBiosystems
SARS-CoV-2 S protein (B.1.351 variant), His Tag	HEK293	SPN-C52Hc	ACROBiosystems
SARS-CoV-2 S protein (B.1.1.28 variant), His Tag	HEK293	SPN-C52Hg	ACROBiosystems

855

856

#### 858 Supplementary Figures



859

Supplementary Figure 1. Binding of PTX3 to captured SARS-CoV-2 Nucleocapsid
 proteins from different companies. Data are presented as mean ± SEM of one experiment
 performed in duplicate.

864



865

866 Supplementary Figure 2. Interaction between recombinant RBD and immobilized MBL in

the presence or absence of calcium, as assessed by SPR analysis.

869



Supplementary Figure 3. Inhibition of viral infection and chemokine production by MBL.
(A-C) Inhibition of the infectivity of the D614G (isolate EPI\_ISL\_413489) (A, B) and B.1.1.7
(C) SARS-CoV-2 variants by MBL in Calu-3 cells. SARS-CoV-2 (A upper panel, B and C,

874	MOI=0.1; A lower panels, MOI=1) was preincubated in complete medium containing different
875	concentrations of MBL (0.01–10 $\mu$ g/mL– 0.034-34 nM) before incubation with Calu-3 cells
876	(Virus + MBL) (A), or both virus and cells were pre-incubated with the same concentrations
877	of MBL (Virus+ Cells+MBL) (B, C). After 48 and 72 h, the infectivity of SARS-CoV-2 present
878	in cell culture supernatants was determined by a plaque-forming assay in Vero cells. NIL: no
879	MBL. (D) SARS-CoV-2 production at the HBEC apical surface at 72 h PI, in the presence of
880	25 or 100 $\mu$ g/ml (75 or 300 nM) PTX3. (E) Chemokine production by SARS-CoV-2 infected
881	HBEC in the presence of MBL. Mean values of two (A, B, D) or one (C, E) experiments in
882	duplicate cell culture are shown. ****p value <0.0001, ***p value <0.001, **p value <0.01 as
883	determined by two-way (A, B, C, E) or one-way (D) ANOVA with Bonferroni's correction.
884	
885 886	Movie S1. SARS-CoV-2 S protein and MBL colocalized on infected HBEC cells. 3D

rendering showing a blended reconstruction of the colocalization between SARS-CoV-2 S

888 protein and MBL in HBEC cultures, preferentially associated to the apical side.

#### 890 **References**

891 Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N.V., Paciello, I., 892 Monego, S.D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020). SARS-CoV-2 escape 893 in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 894 doi.org/10.1101/2020.12.28.424451. 895 Berisio, R., Vitagliano, L., Mazzarella, L., and Zagari, A. (2002). Crystal structure of 896 the collagen triple helix model [(Pro-Pro-Gly)(10)](3). Protein Sci 11, 262-270. 897 Bottazzi, B., Doni, A., Garlanda, C., and Mantovani, A. (2010). An integrated view of 898 humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 28, 157-183. 899 Bottazzi, B., Vouret-Craviari, V., Bastone, A., De Gioia, L., Matteucci, C., Peri, G., 900 Spreafico, F., Pausa, M., D'Ettorre, C., Gianazza, E., et al. (1997). Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short 901 902 pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272, 32817-903 32823. 904 Bozza, S., Bistoni, F., Gaziano, R., Pitzurra, L., Zelante, T., Bonifazi, P., Perruccio, 905 K., Bellocchio, S., Neri, M., Iorio, A.M., et al. (2006). Pentraxin 3 protects from MCMV 906 infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 907 108, 3387-3396. 908 Browning, S.R., and Browning, B.L. (2007). Rapid and accurate haplotype phasing 909 and missing-data inference for whole-genome association studies by use of localized 910 haplotype clustering. Am J Hum Genet 81, 1084-1097. 911 Brunetta, E., Folci, M., Bottazzi, B., De Santis, M., Gritti, G., Protti, A., Mapelli, 912 S.N., Bonovas, S., Piovani, D., Leone, R., et al. (2021). Macrophage expression and 913 prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol 22, 19-24. 914 Carvelli, J., Demaria, O., Vely, F., Batista, L., Chouaki Benmansour, N., Fares, J., 915 Carpentier, S., Thibult, M.L., Morel, A., Remark, R., et al. (2020). Association of COVID-19 916 inflammation with activation of the C5a-C5aR1 axis. Nature 588, 146-150. 917 Casalino, L., Gaieb, Z., Goldsmith, J.A., Hjorth, C.K., Dommer, A.C., Harbison, 918 A.M., Fogarty, C.A., Barros, E.P., Taylor, B.C., McLellan, J.S., et al. (2020). Beyond 919 Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS Cent Sci 6, 1722-920 1734.

921	Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella,
922	S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014). Uncovering and dissecting the
923	genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 22, 774-785.
924	Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J.
925	(2015). Second-generation PLINK: rising to the challenge of larger and richer datasets.
926	Gigascience 4, 7.
927	Chiodo, F., Bruijns, S.C.M., Rodriguez, E., Li, R.J.E., Molinaro, A., Silipo, A., Di
928	Lorenzo, F., Garcia-Rivera, D., Valdes-Balbin, Y., Verez-Bencomo, V., et al. (2020). Novel
929	ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins
930	and Lung Microbiota. bioRxiv, doi.org/10.1101/2020.05.13.092478.
931	Chu, H., Chan, J.F., Yuen, T.T., Shuai, H., Yuan, S., Wang, Y., Hu, B., Yip, C.C.,
932	Tsang, J.O., Huang, X., et al. (2020). Comparative tropism, replication kinetics, and cell
933	damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical
934	manifestations, transmissibility, and laboratory studies of COVID-19: an observational study.
935	Lancet Microbe 1, e14-e23.
936	Clementi, N., Criscuolo, E., Diotti, R.A., Ferrarese, R., Castelli, M., Dagna, L.,
937	Burioni, R., Clementi, M., and Mancini, N. (2020). Combined Prophylactic and Therapeutic
938	Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Front Microbiol 11,
939	1704.
940	Consortium, T.U. (2020). UniProt: the universal protein knowledgebase in 2021.
941	Nucleic Acids Res 49, D480-D489.
942	De Gasparo, R., Pedotti, M., Simonelli, L., Nickl, P., Muecksch, F., Cassaniti, I.,
943	Percivalle, E., Lorenzi, J.C.C., Mazzola, F., Magri, D., et al. (2021). Bispecific IgG
944	neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature 593, 424-428.
945	Desmyter, J., Melnick, J.L., and Rawls, W.E. (1968). Defectiveness of interferon
946	production and of rubella virus interference in a line of African green monkey kidney cells
947	(Vero). J Virol 2, 955-961.
948	Fajgenbaum, D.C., and June, C.H. (2020). Cytokine Storm. N Engl J Med 383, 2255-
949	2273.
950	Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. (2000). Gene
951	transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol
952	sequences. Nat Genet 25, 217-222.

953	Fu, B., Sahakyan, A.B., Camilloni, C., Tartaglia, G.G., Paci, E., Caflisch, A.,
954	Vendruscolo, M., and Cavalli, A. (2014). ALMOST: an all atom molecular simulation toolkit
955	for protein structure determination. J Comput Chem 35, 1101-1105.
956	Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z.,
957	Hu, Y., et al. (2020). Highly pathogenic coronavirus N protein aggravates lung injury by
958	MASP-2-mediated complement over-activation. medRxiv,
959	10.1101/2020.1103.1129.20041962.
960	Garlanda, C., Bottazzi, B., Magrini, E., Inforzato, A., and Mantovani, A. (2018).
961	PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and
962	Cancer. Physiol Rev 98, 623-639.
963	Garred, P., Pressler, T., Lanng, S., Madsen, H.O., Moser, C., Laursen, I., Balstrup, F.,
964	Koch, C., and Koch, C. (2002). Mannose-binding lectin (MBL) therapy in an MBL-deficient
965	patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 33, 201-207.
966	Han, B., Ma, X., Zhang, J., Zhang, Y., Bai, X., Hwang, D.M., Keshavjee, S., Levy,
967	G.A., McGilvray, I., and Liu, M. (2012). Protective effects of long pentraxin PTX3 on lung
968	injury in a severe acute respiratory syndrome model in mice. Lab Invest 92, 1285-1296.
969	Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J.M., and Glaunsinger, B.A.
970	(2020). The molecular virology of coronaviruses. J Biol Chem 295, 12910-12934.
971	Holmskov, U., Thiel, S., and Jensenius, J.C. (2003). Collections and ficolins: humoral
972	lectins of the innate immune defense. Annu Rev Immunol 21, 547-578.
973	Ip, W.K., Chan, K.H., Law, H.K., Tso, G.H., Kong, E.K., Wong, W.H., To, Y.F.,
974	Yung, R.W., Chow, E.Y., Au, K.L., et al. (2005). Mannose-binding lectin in severe acute
975	respiratory syndrome coronavirus infection. J Infect Dis 191, 1697-1704.
976	Jensenius, J.C., Jensen, P.H., McGuire, K., Larsen, J.L., and Thiel, S. (2003).
977	Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans 31, 763-767.
978	Karwaciak, I., Salkowska, A., Karas, K., Dastych, J., and Ratajewski, M. (2021).
979	Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes
980	and Macrophages-Potential Implications for Cytokine Storm Syndrome. Vaccines (Basel) 9,
981	54.
982	King, C., and Sprent, J. (2021). Dual Nature of Type I Interferons in SARS-CoV-2-
983	Induced Inflammation. Trends Immunol 42, 312-322.
984	Koch, A., Melbye, M., Sorensen, P., Homoe, P., Madsen, H.O., Molbak, K., Hansen,
985	C.H., Andersen, L.H., Hahn, G.W., and Garred, P. (2001). Acute respiratory tract infections

and mannose-binding lectin insufficiency during early childhood. JAMA 285, 1316-1321.

987	Lempp, F.A., Soriaga, L., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, YJ.,
988	Bianchi, S., Walls, A.C., Bowen, J.E., Zhou, J., et al. (2021). Membrane lectins enhance
989	SARS-CoV-2 infection and influence the neutralizing activity of different classes of
990	antibodies. bioRxiv, doi.org/10.1101/2021.04.03.438258.
991	Lipscombe, R.J., Sumiya, M., Hill, A.V., Lau, Y.L., Levinsky, R.J., Summerfield,
992	J.A., and Turner, M.W. (1992). High frequencies in African and non-African populations of
993	independent mutations in the mannose binding protein gene. Hum Mol Genet 1, 709-715.
994	Lu, Q., Liu, J., Zhao, S., Gomez Castro, M.F., Laurent-Rolle, M., Dong, J., Ran, X.,
995	Damani-Yokota, P., Tang, H., Karakousi, T., et al. (2021). SARS-CoV-2 exacerbates
996	proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety
997	family member 2. Immunity. doi: 10.1016/j.immuni.2021.05.006. In press.
998	Madsen, H.O., Garred, P., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., Thiel, S., and
999	Svejgaard, A. (1994). A new frequent allele is the missing link in the structural
1000	polymorphism of the human mannan-binding protein. Immunogenetics 40, 37-44.
1001	Madsen, H.O., Garred, P., Thiel, S., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., and
1002	Svejgaard, A. (1995). Interplay between promoter and structural gene variants control basal
1003	serum level of mannan-binding protein. J Immunol 155, 3013-3020.
1004	Mantel, N., and Haenszel, W. (1959). Statistical aspects of the analysis of data from
1005	retrospective studies of disease. J Natl Cancer Inst 22, 719-748.
1006	McBride, R., van Zyl, M., and Fielding, B.C. (2014). The coronavirus nucleocapsid is
1007	a multifunctional protein. Viruses 6, 2991-3018.
1008	Medetalibeyoglu, A., Bahat, G., Senkal, N., Kose, M., Avci, K., Sayin, G.Y., Isoglu-
1009	Alkac, U., Tukek, T., and Pehlivan, S. (2021). Mannose binding lectin gene 2 (rs1800450)
1010	missense variant may contribute to development and severity of COVID-19 infection. Infect
1011	Genet Evol 89, 104717.
1012	Merad, M., and Martin, J.C. (2020). Pathological inflammation in patients with
1013	COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20, 355-362.
1014	Mycroft-West, C.J., Su, D., Pagani, I., Rudd, T.R., Elli, S., Gandhi, N.S., Guimond,
1015	S.E., Miller, G.J., Meneghetti, M.C.Z., Nader, H.B., et al. (2020). Heparin Inhibits Cellular
1016	Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1
1017	Receptor-Binding Domain with Heparin. Thromb Haemost 120, 1700-1715.
1018	Myocardial Infarction Genetics, C., Kathiresan, S., Voight, B.F., Purcell, S.,
1019	Musunuru, K., Ardissino, D., Mannucci, P.M., Anand, S., Engert, J.C., Samani, N.J., et al.

1020	(2009). Genome-wide association of early-onset myocardial infarction with single nucleotide
1021	polymorphisms and copy number variants. Nat Genet 41, 334-341.
1022	Ng, K.K., Kolatkar, A.R., Park-Snyder, S., Feinberg, H., Clark, D.A., Drickamer, K.,
1023	and Weis, W.I. (2002). Orientation of bound ligands in mannose-binding proteins.
1024	Implications for multivalent ligand recognition. J Biol Chem 277, 16088-16095.
1025	Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D.,
1026	Walker, S., Parkinson, N., Fourman, M.H., Russell, C.D., et al. (2021). Genetic mechanisms
1027	of critical illness in COVID-19. Nature 591, 92-98.
1028	Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D.,
1029	Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-
1030	genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575.
1031	Reading, P.C., Bozza, S., Gilbertson, B., Tate, M., Moretti, S., Job, E.R., Crouch,
1032	E.C., Brooks, A.G., Brown, L.E., Bottazzi, B., et al. (2008). Antiviral Activity of the Long
1033	Chain Pentraxin PTX3 against Influenza Viruses. J Immunol 180, 3391-3398.
1034	Risitano, A.M., Mastellos, D.C., Huber-Lang, M., Yancopoulou, D., Garlanda, C.,
1035	Ciceri, F., and Lambris, J.D. (2020). Complement as a target in COVID-19? Nat Rev
1036	Immunol 20, 343-344.
1037	Schirinzi, A., Pesce, F., Laterza, R., D'Alise, M.G., Lovero, R., Fontana, A., Contino,
1038	R., and Di Serio, F. (2021). Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients
1039	admitted to the emergency department. J Infect 82, 84-123.
1040	Scudieri, P., Caci, E., Bruno, S., Ferrera, L., Schiavon, M., Sondo, E., Tomati, V.,
1041	Gianotti, A., Zegarra-Moran, O., Pedemonte, N., et al. (2012). Association of TMEM16A
1042	chloride channel overexpression with airway goblet cell metaplasia. J Physiol 590, 6141-
1043	6155.
1044	Severe Covid, G.G., Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos,
1045	A., Invernizzi, P., Fernandez, J., Prati, D., Baselli, G., et al. (2020). Genomewide Association
1046	Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 383, 1522-1534.
1047	Sheriff, S., Chang, C.Y., and Ezekowitz, R.A.B. (1994). Human mannose-binding
1048	protein carbohydrate recognition domain trimerizes through a triple $\alpha$ -helical coiled-coil. Nat
1049	Struct Biol 1, 789-794.
1050	Stravalaci, M., Davi, F., Parente, R., Gobbi, M., Bottazzi, B., Mantovani, A., Day,
1051	A.J., Clark, S.J., Romano, M.R., and Inforzato, A. (2020). Control of Complement Activation
1052	by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration. Front
1053	Pharmacol 11, 591908.

1054	Sumiya, M., Super, M., Tabona, P., Levinsky, R.J., Arai, T., Turner, M.W., and
1055	Summerfield, J.A. (1991). Molecular basis of opsonic defect in immunodeficient children.
1056	Lancet 337, 1569-1570.
1057	Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun,
1058	S.A.G., Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831
1059	diverse genomes from the NHLBI TOPMed Program. Nature 590, 290-299.
1060	Wang, J., Jiang, M., Chen, X., and Montaner, L.J. (2020). Cytokine storm and
1061	leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19
1062	patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 108, 17-41.
1063	Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S., and Crispin, M. (2020). Site-
1064	specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330-333.
1065	Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W.,
1066	Tian, J.H., Pei, Y.Y., et al. (2020). A new coronavirus associated with human respiratory
1067	disease in China. Nature 579, 265-269.
1068	Yuan, F.F., Tanner, J., Chan, P.K., Biffin, S., Dyer, W.B., Geczy, A.F., Tang, J.W.,
1069	Hui, D.S., Sung, J.J., and Sullivan, J.S. (2005). Influence of FcgammaRIIA and MBL
1070	polymorphisms on severe acute respiratory syndrome. Tissue Antigens 66, 291-296.
1071	Zeng, W., Liu, G., Ma, H., Zhao, D., Yang, Y., Liu, M., Mohammed, A., Zhao, C.,
1072	Yang, Y., Xie, J., et al. (2020). Biochemical characterization of SARS-CoV-2 nucleocapsid
1073	protein. Biochem Biophys Res Commun 527, 618-623.
1074	Zhang, H., Zhou, G., Zhi, L., Yang, H., Zhai, Y., Dong, X., Zhang, X., Gao, X., Zhu,
1075	Y., and He, F. (2005). Association between mannose-binding lectin gene polymorphisms and
1076	susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 192,
1077	1355-1361.
1078	Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M.,
1079	Sabli, I.K.D., Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in
1080	patients with life-threatening COVID-19. Science 370, eabd4570.
1081	Zhou, Y., Lu, K., Pfefferle, S., Bertram, S., Glowacka, I., Drosten, C., Pohlmann, S.,
1082	and Simmons, G. (2010). A single asparagine-linked glycosylation site of the severe acute
1083	respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-
1084	binding lectin through multiple mechanisms. J Virol 84, 8753-8764.
1085	Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi,
1086	W., Lu, R., et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019.
1087	N Engl J Med 382, 727-733.